Literature DB >> 25752714

Infectious complications in bullous pemphigoid: an analysis of risk factors.

Yee Wei Phoon1, Stephanie M C Fook-Chong2, Hong Yi Koh1, Thamotharampillai Thirumoorthy3, Shiu Ming Pang3, Haur Yueh Lee4.   

Abstract

BACKGROUND: Infections are common in bullous pemphigoid and contribute to significant mortality.
OBJECTIVES: We sought to define the spectrum of infectious complications and to identify associated risk factors in a bullous pemphigoid cohort.
DESIGN: A retrospective cohort study conducted at an academic medical center.
RESULTS: In all, 97 patients were included. Infectious complications occurred in 54 patients (56%) and the median duration from diagnosis to first episode of infection was 3 months. Bacteremia occurred in 14 patients (26%) and 26 of 30 deaths (87%) were attributable to infections. On univariate analysis, significant risk factors include low Karnofsky score (<60) (odds ratio [OR] 3.5, 95% confidence interval [CI] 1.5-8.3; P < .01), high Charlson comorbidity index score (≥6) (OR 2.4, 95% CI 1.1-5.5; P = .04), and dementia (OR 4.9, 95% CI 1.5-15.8; P = .01). On multivariate analysis, low Karnofsky score and dementia remained significant with an OR of 3.3 (95% CI 1.1-10.0; P = .03) and OR of 4.2 (95% CI 1.2-14.7; P = .03), respectively. LIMITATIONS: Limitations include potential selection bias as a result of study design and primary outcome measures focused on significant infections requiring hospitalizations. Minor infections were not included.
CONCLUSIONS: Identified risk factors for infectious complications include functional impairment and the presence of dementia, which may allow for better risk stratification and individualized treatment of bullous pemphigoid.
Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  bullous pemphigoid; dementia; infectious complications; low Karnofsky score; morbidity; mortality; risk factors

Mesh:

Year:  2015        PMID: 25752714     DOI: 10.1016/j.jaad.2015.01.029

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

Review 1.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 2.  Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations.

Authors:  Khalaf Kridin
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

Review 3.  Cutaneous Exophiala oligosperma Infection in a Patient with Bullous Pemphigoid with a Review of the Literature.

Authors:  Chau Yee Ng; Sybren de Hoog; Hua-En Li; Yung-Yi Lee; Chun-Bing Chen; Pei-Lun Sun
Journal:  Mycopathologia       Date:  2016-12-26       Impact factor: 2.574

4.  Herpes zoster in patients with bullous pemphigoid: a population-based case-control and cohort study.

Authors:  B J Barrick; J D Barrick; C H Weaver; C M Lohse; C N Wieland; A N Kalaaji; J S Lehman
Journal:  Br J Dermatol       Date:  2016-02-04       Impact factor: 9.302

5.  Biological predictors shared by dementia and bullous pemphigoid patients point out a cross-antigenicity between BP180/BP230 brain and skin isoforms.

Authors:  Tamiris A Julio; Sebastian Vernal; Juliana D Massaro; Matheus C Silva; Eduardo A Donadi; Julio C Moriguti; Ana M Roselino
Journal:  Immunol Res       Date:  2018-10       Impact factor: 2.829

6.  Three case reports of post immunization and post viral Bullous Pemphigoid: looking for the right trigger.

Authors:  Luca Baroero; Paola Coppo; Laura Bertolino; Stefano Maccario; Francesco Savino
Journal:  BMC Pediatr       Date:  2017-02-23       Impact factor: 2.125

7.  IL-13 Genetic Susceptibility to Bullous Pemphigoid: A Potential Target for Treatment and a Prognostic Marker.

Authors:  Yiman Wang; Xuming Mao; Yangchun Liu; Yuyan Yang; Hongzhong Jin; Li Li
Journal:  Front Immunol       Date:  2022-01-24       Impact factor: 7.561

Review 8.  Molecular Basis for Global Incidence of Pemphigoid Diseases and Differences in Phenotypes.

Authors:  A Razzaque Ahmed; Sarah Anwar; Pedro A Reche
Journal:  Front Immunol       Date:  2022-01-21       Impact factor: 7.561

9.  Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.

Authors:  Peng Cao; Wenjing Xu; Litao Zhang
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

10.  Assessment of the Characteristics and Associated Factors of Infectious Complications in Bullous Pemphigoid.

Authors:  Jia Chen; Xuming Mao; Wenling Zhao; Bingjie Zhang; Xinyi Chen; Chenyang Yu; Zehui Zheng; Hongzhong Jin; Li Li
Journal:  Front Immunol       Date:  2020-07-23       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.